...well, if happens here it'll be on the basis of actual data...

...well, if happens here it'll be on the basis of actual data from a FDA controlled clinical trial...
just saying: it is amazing how a company can double its MC overnight before presenting the data on which that doubling is based.....it actually missed its primary end point and has released no data on the other primary end point that it claimed to hit....by comparison RAP and MSB went down on what were arguably better results..? BOT's has a management that has multiple FDA approved drugs on their record, about to start its second Phase2 trial targeting conditions that account for multibillion dollars of yearly revenues and .....is in a downtrend....That's the market I guess.